Scholarlink

<p>Somatic mutations in <i>KRAS</i> are a common driver of colorectal cancer (CRC) and present at different frequencies by race, sex, tumor site, ethnicity, and genetic similarity. Inherited germline variants may influence tumor somatic mutation frequency by altering mutation or DNA repair processes or altering cellular, immunological and/or microenvironmental responses after a mutation. We hypothesized that the germline genetic background modifies somatic <i>KRAS</i> mutation frequency in CRC. To test this, we performed a genome-wide association study (GWAS) in 7071 individuals with CRC, using <i>KRAS</i> mutation status as the phenotype. Single-nucleotide variants were chosen for validation analyses based on <i>P</i> values from the discovery GWAS, predicted in silico functional effects, and proximity to genes with potential cancer relevance. A validation analysis of 101 SNVs of interest was performed in 2482 individuals. No SNVs were significantly associated with <i>KRAS</i>-mutant CRC (<i>P</i> value &lt; 0.0005). One variant rs73067863-T showed a non-significant exploratory association with fewer <i>KRAS</i>-mutant tumors in the combined sample (<i>P</i> value = 9.7 × 10<sup>–7</sup>, OR = 0.75). Follow-up studies are needed to determine if these or other germline variants impact population differences in <i>KRAS</i> mutations in CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of germline variants with KRAS-mutation status in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Nijole Pollock Tjader,
  • Johnny Ramroop,
  • Tanish Gandhi,
  • Cara Dauch,
  • Owen Meadows,
  • Patrick Stevens,
  • Rachel Pearlman,
  • Heather Hampel,
  • Elom K. Aglago,
  • Sonja I. Berndt,
  • Amanda Bloomer,
  • Hermann Brenner,
  • Daniel D. Buchanan,
  • Peter T. Campbell,
  • Yin Cao,
  • Andrew T. Chan,
  • Iona Cheng,
  • Niki Dimou,
  • David A. Drew,
  • Amy J. French,
  • Peter Georgeson,
  • Marios Giannakis,
  • Graham G. Giles,
  • Maria Gomez,
  • Stephen B. Gruber,
  • Michael Hoffmeister,
  • Wen-Yi Huang,
  • Meredith A. J. Hullar,
  • Jeroen R. Huyghe,
  • Nicole Loroña,
  • Victor Moreno,
  • Christina C. Newton,
  • Jonathan A. Nowak,
  • Mireia Obón-Santacana,
  • Shuji Ogino,
  • Andrew Pellatt,
  • Anita R. Peoples,
  • Jennifer B. Permuth,
  • Stephanie L. Schmit,
  • Robert E. Schoen,
  • Erin M. Siegel,
  • Robert S. Steinfelder,
  • Wei Sun,
  • Jamie K. Teer,
  • Claire E. Thomas,
  • Quang M. Trinh,
  • Konstantinos Tsilidis,
  • Tomotaka Ugai,
  • Caroline Y. Um,
  • Bethany Van Guelpen,
  • Syed H. Zaidi,
  • Jane Figueiredo,
  • Ulrike Peters,
  • Amanda I. Phipps,
  • Joseph Paul McElroy,
  • Amanda Ewart Toland

摘要

Somatic mutations in KRAS are a common driver of colorectal cancer (CRC) and present at different frequencies by race, sex, tumor site, ethnicity, and genetic similarity. Inherited germline variants may influence tumor somatic mutation frequency by altering mutation or DNA repair processes or altering cellular, immunological and/or microenvironmental responses after a mutation. We hypothesized that the germline genetic background modifies somatic KRAS mutation frequency in CRC. To test this, we performed a genome-wide association study (GWAS) in 7071 individuals with CRC, using KRAS mutation status as the phenotype. Single-nucleotide variants were chosen for validation analyses based on P values from the discovery GWAS, predicted in silico functional effects, and proximity to genes with potential cancer relevance. A validation analysis of 101 SNVs of interest was performed in 2482 individuals. No SNVs were significantly associated with KRAS-mutant CRC (P value < 0.0005). One variant rs73067863-T showed a non-significant exploratory association with fewer KRAS-mutant tumors in the combined sample (P value = 9.7 × 10–7, OR = 0.75). Follow-up studies are needed to determine if these or other germline variants impact population differences in KRAS mutations in CRC.